{"doc_id": "32876695", "type of study": "Therapy", "title": "", "abstract": "Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.\nImportance : Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) is associated with substantial mortality and use of health care resources.\nDexamethasone use might attenuate lung injury in these patients.\nObjective : To determine whether intravenous dexamethasone increases the number of ventilator-free days among patients with COVID-19-associated ARDS.\nDesign, Setting, and Participants : Multicenter, randomized, open-label, clinical trial conducted in 41 intensive care units (ICUs) in Brazil.\nPatients with COVID-19 and moderate to severe ARDS, according to the Berlin definition, were enrolled from April 17 to June 23, 2020.\nFinal follow-up was completed on July 21, 2020.\nThe trial was stopped early following publication of a related study before reaching the planned sample size of 350 patients.\nInterventions : Twenty mg of dexamethasone intravenously daily for 5 days, 10 mg of dexamethasone daily for 5 days or until ICU discharge, plus standard care (n\u2009=151) or standard care alone (n\u2009=\u2009148).\nMain Outcomes and Measures : The primary outcome was ventilator-free days during the first 28 days, defined as being alive and free from mechanical ventilation.\nSecondary outcomes were all-cause mortality at 28 days, clinical status of patients at day 15 using a 6-point ordinal scale (ranging from 1, not hospitalized to 6, death), ICU-free days during the first 28 days, mechanical ventilation duration at 28 days, and Sequential Organ Failure Assessment (SOFA) scores (range, 0-24, with higher scores indicating greater organ dysfunction) at 48 hours, 72 hours, and 7 days.\nResults : A total of 299 patients (mean [SD] age, 61 [14] years; 37% women) were enrolled and all completed follow-up.\nPatients randomized to the dexamethasone group had a mean 6.6 ventilator-free days (95% CI, 5.0-8.2) during the first 28 days vs 4.0 ventilator-free days (95% CI, 2.9-5.4) in the standard care group (difference, 2.26; 95% CI, 0.2-4.38; P\u2009=\u2009.04).\nAt 7 days, patients in the dexamethasone group had a mean SOFA score of 6.1 (95% CI, 5.5-6.7) vs 7.5 (95% CI, 6.9-8.1) in the standard care group (difference, -1.16; 95% CI, -1.94 to -0.38; P = .004).\nThere was no significant difference in the prespecified secondary outcomes of all-cause mortality at 28 days, ICU-free days during the first 28 days, mechanical ventilation duration at 28 days, or the 6-point ordinal scale at 15 days.\nThirty-three patients (21.9%) in the dexamethasone group vs 43 (29.1%) in the standard care group experienced secondary infections, 47 (31.1%) vs 42 (28.3%) needed insulin for glucose control, and 5 (3.3%) vs 9 (6.1%) experienced other serious adverse events.\nConclusions and Relevance : Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over 28 days.\nTrial Registration : ClinicalTrials.gov Identifier: NCT04327401.\n", "Evidence Map": {"Enrollment": [{"term": "Moderate or Severe Acute Respiratory Distress Syndrome", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 129}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 134, "end": 142}, {"term": "COVID-19-associated ARDS", "negation": "affirmed", "UMLS": {}, "start": 124, "end": 148}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 22}, {"term": "moderate to severe ARDS", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 50}, {"term": "ICU discharge", "negation": "affirmed", "UMLS": {}, "start": 125, "end": 138}, {"term": "alive", "negation": "negated", "UMLS": {}, "start": 118, "end": 123}, {"term": "free from mechanical", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 148}, {"term": "COVID-19", "negation": "negated", "UMLS": {}, "start": 48, "end": 56}, {"term": "moderate or severe ARDS", "negation": "negated", "UMLS": {}, "start": 61, "end": 84}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 : The CoDEX Randomized Clinical Trial .", "Evidence Elements": {"Participant": [{"term": "Moderate or Severe Acute Respiratory Distress Syndrome", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 129}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 134, "end": 142}], "Intervention": [{"term": "Dexamethasone", "negation": "negated", "UMLS": {}, "start": 10, "end": 23, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}], "Outcome": [{"term": "Days Alive", "negation": "negated", "UMLS": {}, "start": 27, "end": 37}, {"term": "Ventilator-Free", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 57}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Importance : Acute respiratory distress syndrome ( ARDS ) due to coronavirus disease 2019 ( COVID-19 ) is associated with substantial mortality and use of health care resources .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Dexamethasone use might attenuate lung injury in these patients .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 13, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}], "Outcome": [{"term": "lung injury", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 45}], "Observation": [{"term": "attenuate", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 33}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Objective : To determine whether intravenous dexamethasone increases the number of ventilator-free days among patients with COVID-19-associated ARDS .", "Evidence Elements": {"Participant": [{"term": "COVID-19-associated ARDS", "negation": "affirmed", "UMLS": {}, "start": 124, "end": 148}], "Intervention": [{"term": "intravenous dexamethasone", "negation": "negated", "UMLS": {}, "start": 33, "end": 58, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 12, "end": 25, "has_route": ["intravenous"]}], "has_relation": "N/A"}], "Outcome": [{"term": "number of ventilator-free days", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 103}], "Observation": [{"term": "increases", "negation": "negated", "UMLS": {}, "start": 59, "end": 68}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Design , Setting , and Participants : Multicenter , randomized , open-label , clinical trial conducted in 41 intensive care units ( ICUs ) in Brazil .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Patients with COVID-19 and moderate to severe ARDS , according to the Berlin definition , were enrolled from April 17 to June 23 , 2020 .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 22}, {"term": "moderate to severe ARDS", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 50}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Final follow-up was completed on July 21 , 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The trial was stopped early following publication of a related study before reaching the planned sample size of 350 patients .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Interventions : Twenty mg of dexamethasone intravenously daily for 5 days , 10 mg of dexamethasone daily for 5 days or until ICU discharge , plus standard care ( n = 151 ) or standard care alone ( n = 148 ) .", "Evidence Elements": {"Participant": [{"term": "ICU discharge", "negation": "affirmed", "UMLS": {}, "start": 125, "end": 138}], "Intervention": [{"term": "dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 42, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, {"term": "dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 42, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, {"term": "standard care", "negation": "affirmed", "UMLS": {}, "start": 146, "end": 159, "has_relation": "N/A"}, {"term": "standard", "negation": "affirmed", "UMLS": {}, "start": 146, "end": 154, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Main Outcomes and Measures : The primary outcome was ventilator-free days during the first 28 days , defined as being alive and free from mechanical ventilation .", "Evidence Elements": {"Participant": [{"term": "alive", "negation": "negated", "UMLS": {}, "start": 118, "end": 123}, {"term": "free from mechanical", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 148}], "Intervention": [], "Outcome": [{"term": "ventilator-free days", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 73}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Secondary outcomes were all-cause mortality at 28 days , clinical status of patients at day 15 using a 6-point ordinal scale ( ranging from 1 , not hospitalized to 6 , death ) , ICU-free days during the first 28 days , mechanical ventilation duration at 28 days , and Sequential Organ Failure Assessment ( SOFA ) scores ( range , 0-24 , with higher scores indicating greater organ dysfunction ) at 48 hours , 72 hours , and 7 days .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "all-cause mortality", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 43}, {"term": "clinical status", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 72}, {"term": "patients", "negation": "affirmed", "UMLS": {}, "start": 76, "end": 84}, {"term": "ICU-free days", "negation": "affirmed", "UMLS": {}, "start": 178, "end": 191}, {"term": "mechanical ventilation duration", "negation": "affirmed", "UMLS": {}, "start": 219, "end": 250}, {"term": "Sequential Organ Failure Assessment ( SOFA ) scores", "negation": "affirmed", "UMLS": {}, "start": 268, "end": 319}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Results : A total of 299 patients ( mean [ SD ] age , 61 [ 14 ] years ; 37 % women ) were enrolled and all completed follow-up .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Patients randomized to the dexamethasone group had a mean 6.6 ventilator-free days ( 95 % CI , 5.0-8.2 ) during the first 28 days vs 4.0 ventilator-free days ( 95 % CI , 2.9-5.4 ) in the standard care group ( difference , 2.26 ; 95 % CI , 0.2-4.38 ; P = .04 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "dexamethasone", "negation": "negated", "UMLS": {}, "start": 27, "end": 40, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, {"term": "standard care", "negation": "affirmed", "UMLS": {}, "start": 187, "end": 200, "has_relation": "N/A"}], "Outcome": [{"term": "mean", "negation": "negated", "UMLS": {}, "start": 53, "end": 57}], "Observation": [{"term": "6.6 ventilator-free days", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 82}, {"term": "4.0 ventilator-free days", "negation": "affirmed", "UMLS": {}, "start": 133, "end": 157}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "At 7 days , patients in the dexamethasone group had a mean SOFA score of 6.1 ( 95 % CI , 5.5-6.7 ) vs 7.5 ( 95 % CI , 6.9-8.1 ) in the standard care group ( difference , -1.16 ; 95 % CI , -1.94 to -0.38 ; P =.004 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 41, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, {"term": "standard care", "negation": "affirmed", "UMLS": {}, "start": 135, "end": 148, "has_relation": "N/A"}], "Outcome": [{"term": "mean SOFA score", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 69}], "Observation": [{"term": "6.1", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 76}, {"term": "7.5", "negation": "affirmed", "UMLS": {}, "start": 102, "end": 105}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "dexamethasone", "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, "Observation": "6.1", "Outcome": "mean SOFA score", "Count": ""}, {"Intervention": {"term": "standard care", "has_relation": "N/A"}, "Observation": "7.5", "Outcome": "mean SOFA score", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "There was no significant difference in the prespecified secondary outcomes of all-cause mortality at 28 days , ICU-free days during the first 28 days , mechanical ventilation duration at 28 days , or the 6-point ordinal scale at 15 days .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "prespecified secondary outcomes", "negation": "negated", "UMLS": {}, "start": 43, "end": 74}, {"term": "all-cause mortality", "negation": "negated", "UMLS": {}, "start": 78, "end": 97}, {"term": "ICU-free days", "negation": "affirmed", "UMLS": {}, "start": 111, "end": 124}, {"term": "mechanical ventilation duration", "negation": "affirmed", "UMLS": {}, "start": 152, "end": 183}, {"term": "6-point ordinal scale", "negation": "affirmed", "UMLS": {}, "start": 204, "end": 225}], "Observation": [{"term": "significant difference", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 35}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "significant difference", "Outcome": "prespecified secondary outcomes", "Count": ""}, {"Intervention": [], "Observation": "significant difference", "Outcome": "all-cause mortality", "Count": ""}, {"Intervention": [], "Observation": "significant difference", "Outcome": "ICU-free days", "Count": ""}, {"Intervention": [], "Observation": "significant difference", "Outcome": "mechanical ventilation duration", "Count": ""}, {"Intervention": [], "Observation": "significant difference", "Outcome": "6-point ordinal scale", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Thirty-three patients ( 21.9 % ) in the dexamethasone group vs 43 ( 29.1 % ) in the standard care group experienced secondary infections , 47 ( 31.1 % ) vs 42 ( 28.3 % ) needed insulin for glucose control , and 5 ( 3.3 % ) vs 9 ( 6.1 % ) experienced other serious adverse events .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 53, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, {"term": "standard care", "negation": "affirmed", "UMLS": {}, "start": 84, "end": 97, "has_relation": "N/A"}], "Outcome": [{"term": "secondary infections", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 136}, {"term": "insulin for", "negation": "affirmed", "UMLS": {}, "start": 177, "end": 188}], "Observation": [], "Count": [{"term": "Thirty-three patients ( 21.9 % )", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 32}, {"term": "43 ( 29.1 % )", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 76}, {"term": "47 ( 31.1 % )", "negation": "affirmed", "UMLS": {}, "start": 139, "end": 152}, {"term": "42 ( 28.3 % )", "negation": "affirmed", "UMLS": {}, "start": 156, "end": 169}]}, "Evidence Propositions": [{"Intervention": {"term": "dexamethasone", "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, "Observation": "", "Count": "Thirty-three patients ( 21.9 % )", "Outcome": "secondary infections"}, {"Intervention": {"term": "standard care", "has_relation": "N/A"}, "Observation": "", "Count": "43 ( 29.1 % )", "Outcome": "secondary infections"}]}, {"Section": "UNKNOWN", "Text": "Conclusions and Relevance : Among patients with COVID-19 and moderate or severe ARDS , use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days ( days alive and free of mechanical ventilation ) over 28 days .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "negated", "UMLS": {}, "start": 48, "end": 56}, {"term": "moderate or severe ARDS", "negation": "negated", "UMLS": {}, "start": 61, "end": 84}], "Intervention": [{"term": "intravenous dexamethasone plus standard care", "negation": "negated", "UMLS": {}, "start": 94, "end": 138, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 12, "end": 25, "has_route": ["intravenous"]}], "has_relation": "N/A"}, {"term": "standard care alone", "negation": "negated", "UMLS": {}, "start": 153, "end": 172, "has_relation": "N/A"}], "Outcome": [{"term": "number of ventilator-free days", "negation": "affirmed", "UMLS": {}, "start": 229, "end": 259}, {"term": "days alive", "negation": "affirmed", "UMLS": {}, "start": 262, "end": 272}, {"term": "of mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 282, "end": 307}], "Observation": [{"term": "statistically significant increase", "negation": "negated", "UMLS": {}, "start": 187, "end": 221}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "intravenous dexamethasone plus standard care", "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 12, "end": 25, "has_route": ["intravenous"]}], "has_relation": "N/A"}, "Observation": "statistically significant increase", "Outcome": "number of ventilator-free days", "Count": ""}, {"Intervention": {"term": "intravenous dexamethasone plus standard care", "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 12, "end": 25, "has_route": ["intravenous"]}], "has_relation": "N/A"}, "Observation": "statistically significant increase", "Outcome": "days alive", "Count": ""}, {"Intervention": {"term": "standard care alone", "has_relation": "N/A"}, "Observation": "statistically significant increase", "Outcome": "number of ventilator-free days", "Count": ""}, {"Intervention": {"term": "standard care alone", "has_relation": "N/A"}, "Observation": "statistically significant increase", "Outcome": "days alive", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Trial Registration : ClinicalTrials.gov Identifier : NCT04327401 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}